Increased tartrate-resistant acid phosphatase serum levels in ankylosing spondylitis and relationship with the inflammatory process

Annals of the Rheumatic Diseases

Volumn 67, Issue 3, 2008, Pages 430-431

  Toussirot, E ^a   Dumoulin, G ^a   Saas, P ^b   Nguyen, N Uyen ^a   Le Huede G ^a   Wendling, D ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; COLLAGEN; OSTEOCALCIN; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; BONE MATRIX; CALCIUM HOMEOSTASIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFLAMMATION; LABORATORY TEST; LETTER; MENOPAUSAL SYNDROME; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCORING SYSTEM;

EID: 39549123007     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.075085     Document Type: Letter

References (10)

1. Toussirot E, Wendling D. Bone mass in ankylosing spondylitis. Clin Exp Rheumatol 2000;18(Suppl 21):S16-S20.
2. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007;19:335-9.
3. Mitra D, Elvins DM, Collins AJ. Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 1999;26:2201- 4.
4. Toussirot E, Ricard-Blum S, Dumoulin G, Cedoz JP, Wendling D. Relationship between urinary pyridinium crosslinks, disease activity and disease subsets of ankylosing spondylitis. Rheumatology 1999;38:21-7.
5. Franck H, Meurer T, Hofbauer, LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
6. Janckila AJ, Nakasato YR, Neustadt DH, Yam LT. Disease-specific expression of tartrate-resistant acid phosphatase isoforms. J Bone Miner Res 2003;18:1916-9.
7. Halleen JM, Tiitinen SL, Ylipahkala H, Fagerlund KM, Väänänen HK. Tartrate-resistant acid phosphatase 5b (TRACP5b) as a marker of bone resorption. Clin Lab 2006;52:499-509.
8. Halleen JM. Tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Anticancer Res 2003;23:1027-9.
9. Gerdhem P, Ivaska KK, Alatalo SL, Hallen JM, Hellman J, Isaksson A, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-93.
10. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimaki T, Schmidt-Gavk H, et al. Serum TRAP5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005;20:1804-12.